Across TCGA pan-cancer cohorts, RTL6 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RTL6 data layer compared with 26 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RTL6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RTL6 expression acts as an unfavorable survival marker.
LUAD are the cancer types where RTL6 mass-spec protein most reproducibly stratifies survival.